Philadelphia, June 13, 2019 – A shift from brain systems controlling reward-driven use to habit-driven use differentiates heavy cannabis users who are addicted to the drug from users who aren’t, according to a study in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, published by Elsevier. The findings help explain how the brain becomes dependent on cannabis, and why not all cannabis users develop an addiction, even with long-term regular use.
In the study, researchers at the University of Electronic Science and Technology of China and University of Bonn, Germany, used brain imaging to monitor neural activity when cannabis users viewed images associated with cannabis use, referred to as drug cues. Although all of the cannabis users in the study reported heavy use, only some were dependent on the drug. Both dependent and non-dependent cannabis users had exaggerated responses in a brain region that processes reward–the ventral striatum–compared with people who didn’t use cannabis. Interestingly, the dependent users also had larger responses in a brain region that forms habits–the dorsal striatum.
“The present findings reflect that heavy cannabis use is promoted by changes in the brain’s reward system–however, these changes alone may not fully explain addictive use. Addictive use may rather be driven by changes in brain systems that promote habitual–automatic–use, which also may explain the fact that addicts continue use despite a lack of experiencing rewarding effects of the drug. As such, their behavior has become under the control of the drug cues, rather than the actual reward expectation,” said lead author Benjamin Becker, PhD.
Dependent users also had increased responses in other regions throughout the brain, including regions that attribute importance to things, for example, drug cues. This suggests that the development of cannabis addiction incorporates additional brain regions that may strengthen a person’s desire to seek the drug.
“Cannabis is now legal for medical and recreational use in many parts of the United States and the health impacts of this development are still being understood,” said Cameron Carter, MD, Editor of Biological Psychiatry: Cognitive Neuroscience and Neuroimaging. “These findings are important insights that can help us better understand why some individuals might be more likely to become addicted to cannabis,” he added.
Differentiating the unique brain circuits behind dependent cannabis use could also be useful for understanding how to combat the problem of cannabis addiction. “The identification of the dorsal striatum and habitual behavior as a driver of addiction may allow the development of more specific treatment approaches to increase treatment success,” said first author Xinqi Zhou.
Notes for editors
The article is “Cue-reactivity in the ventral striatum characterizes heavy cannabis use, whereas reactivity in the dorsal striatum mediates dependent use,” by Xinqi Zhou, Kaeli Zimmermann, Fei Xin, Weihua Zhao, Roelinka T. Derckx, Anja Sassmannshausen, Dirk Scheele, Rene Hurlemann, Bernd Weber, Keith M. Kendrick, and Benjamin Becker (). It appears in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, published by Elsevier.
Copies of this paper are available to credentialed journalists upon request; please contact Rhiannon Bugno at BPCNNI@sobp.org or +1 214 648 0880. Journalists wishing to interview the authors may contact Benjamin Becker, PhD, at firstname.lastname@example.org or +86 2861 830 811.
The authors’ affiliations and disclosures of financial and conflicts of interests are available in the article.
Cameron S. Carter, MD, is Professor of Psychiatry and Psychology and Director of the Center for Neuroscience at the University of California, Davis. His disclosures of financial and conflicts of interests are available here.
About Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging is an official journal of the Society of Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal focuses on studies using the tools and constructs of cognitive neuroscience, including the full range of non-invasive neuroimaging and human extra- and intracranial physiological recording methodologies. It publishes both basic and clinical studies, including those that incorporate genetic data, pharmacological challenges, and computational modeling approaches.
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including and , 39,000 e-book titles and many iconic reference works, including Gray’s Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries.
Rhiannon Bugno, Editorial Office
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
+1 214 648 0880
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.